Incannex Healthcare Inc. (IXHL)

NASDAQ: IXHL · Real-Time Price · USD
0.6240
-0.0140 (-2.19%)
At close: Sep 3, 2025, 4:00 PM
0.6214
-0.0026 (-0.42%)
After-hours: Sep 3, 2025, 4:10 PM EDT
-2.19%
Market Cap58.22M
Revenue (ttm)98,000
Net Income (ttm)-21.74M
Shares Out 93.70M
EPS (ttm)-1.21
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume30,789,139
Open0.6200
Previous Close0.6380
Day's Range0.6110 - 0.6420
52-Week Range0.0800 - 3.1200
Beta2.70
Analystsn/a
Price Targetn/a
Earnings DateSep 29, 2025

About IXHL

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that has completed Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It... [Read more]

Sector Healthcare
Founded 2001
Employees 9
Stock Exchange NASDAQ
Ticker Symbol IXHL
Full Company Profile

Financial Performance

Financial Statements

News

Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

MELBOURNE, Australia and NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”) is pleased to report positive data from its Phase 2 clinical ...

8 days ago - GlobeNewsWire

Incannex Healthcare Authorizes $20 Million Share Repurchase Program

MELBOURNE, Australia and NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company developing innova...

12 days ago - GlobeNewsWire

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025 - Update

Dallas, Texas--(Newsfile Corp. - August 19, 2025) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). Recently, IXH...

14 days ago - Newsfile Corp

Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

MELBOURNE, Australia and NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage pharmaceutical company developing innovative combination therapies for pr...

26 days ago - GlobeNewsWire

Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term

MELBOURNE, Australia, July 31, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”) announced, in response to recent questions it received from a number of it...

4 weeks ago - GlobeNewsWire

Nano-Cap Incannex's Sleep Apnea Candidate Shows Effectiveness And Safety In Mid-Stage Trial

On Wednesday, Incannex Healthcare Inc. IXHL released topline results from its RePOSA Phase 2 clinical trial evaluating IHL-42X, a novel oral drug candidate for obstructive sleep apnea (OSA), a conditi...

5 weeks ago - Benzinga

Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X

Statistically and clinically significant improvements across key clinical endpoints; IHL-42X reduced AHI by up to 83% from baseline. IHL-42X demonstrates compelling clinical benefit and an outstanding...

5 weeks ago - GlobeNewsWire

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo

NEW YORK and MELBOURNE, Australia, July 25, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing combina...

5 weeks ago - GlobeNewsWire

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch

NEW YORK and MELBOURNE, Australia, June 24, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing combina...

2 months ago - GlobeNewsWire

Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X

NEW YORK and MELBOURNE, Australia, June 18, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing combina...

2 months ago - GlobeNewsWire

Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy

Expanded platform improves access, scales operations, and advances Incannex's position in next-generation mental health treatment Expanded platform improves access, scales operations, and advances Inc...

2 months ago - GlobeNewsWire

Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

Capital structure streamlined and potential dilution from Series A Warrants eliminated ahead of key Phase 2 clinical milestones Capital structure streamlined and potential dilution from Series A Warra...

2 months ago - GlobeNewsWire

Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program

NEW YORK and MELBOURNE, Australia, June 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company leading the way i...

3 months ago - GlobeNewsWire

Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance

NEW YORK and MELBOURNE, Australia, May 29, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage pharmaceutical company developing novel combination therapies, today annou...

3 months ago - GlobeNewsWire

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025

Dallas, Texas--(Newsfile Corp. - May 28, 2025) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). During the third...

3 months ago - Newsfile Corp

Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results

MELBOURNE, Australia and NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-im...

3 months ago - GlobeNewsWire

Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution

Raises $12.5M via ATM to Strengthen Shareholder Position Ahead of IHL-42X Phase 2 Data Raises $12.5M via ATM to Strengthen Shareholder Position Ahead of IHL-42X Phase 2 Data

3 months ago - GlobeNewsWire

Incannex Announces Potential Reduction of Up to 50.4% of its Series A Warrants

NEW YORK and MELBOURNE, Australia, May 16, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (“Incannex”), a clinical-stage biopharmaceutical company leading the way in developing oral...

3 months ago - GlobeNewsWire

Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates

NEW YORK and MELBOURNE, Australia, May 15, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral c...

3 months ago - GlobeNewsWire

Incannex Healthcare (IXHL) Stock Soars Over 800%: What's Going On?

Incannex Healthcare Inc IXHL shares surged 876% to 83 cents on Wednesday after the company announced the completion of patient dosing in the Phase 2 portion of its Phase 2/3 RePOSA trial for IHL-42X, ...

4 months ago - Benzinga

Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

Patient dosing completed in Phase 2 portion of Phase 2/3 RePOSA study evaluating IHL-42X oral treatment for OSA. End-of-study follow-up assessments on track for completion by May 17, 2025.

4 months ago - GlobeNewsWire

Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

NEW YORK and MELBOURNE, Australia, April 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing new ...

5 months ago - GlobeNewsWire

Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules

Funds to support the advancement of Incannex's IHL-42X Phase 2/3 Obstructive Sleep Apnea (OSA) clinical program through U.S. Phase 2 completion, topline readout, and its expansion into a global Phase ...

6 months ago - GlobeNewsWire

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025

Dallas, Texas--(Newsfile Corp. - February 18, 2025) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). During the ...

7 months ago - Newsfile Corp

Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates

NEW YORK and MELBOURNE, Australia, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral ...

7 months ago - GlobeNewsWire